Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data

Abstract Objective: To examine the rates of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia and in non-schizophrenic controls. Design: Cohort study of outpatients using administrative data. Setting: 3 US Medicaid programmes. Participants: Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis. Main outcome measure: Diagnosis of cardiac arrest or ventricular arrhythmia. Results: Patients with treated schizophrenia had higher rates of cardiac arrest and ventricular arrhythmia than controls, with rate ratios ranging from 1.7 to 3.2. Overall, thioridazine was not associated with an increased risk compared with haloperidol (rate ratio 0.9, 95% confidence interval 0.7 to 1.2). However, thioridazine showed an increased risk of events at doses 600 mg (2.6, 1.0 to 6.6; P=0.049) and a linear dose-response relation (P=0.038). Conclusions: The increased risk of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia could be due to the disease or its treatment. Overall, the risk with thioridazine was no worse than that with haloperidol. Thioridazine may, however, have a higher risk at high doses, although this finding could be due to chance. To reduce cardiac risk, thioridazine should be prescribed at the lowest dose needed to obtain an optimal therapeutic effect. What is already known on this topic Thioridazine seems to prolong the electrocardiographic QT interval more than haloperidol Although QT prolongation is used as a marker of arrhythmogenicity, it is unknown whether thioridazine is any worse than haloperidol with regard to cardiac safety What this study adds Patients taking antipsychotic drugs had higher risks of cardiac events than control patients with glaucoma or psoriasis Overall, the risk of cardiac arrest and ventricular arrhythmia was not higher with thioridazine than haloperidol Thioridazine may carry a greater risk than haloperidol at high doses Patients should be treated with the lowest dose of thioridazine needed to treat their symptoms

[1]  W. Amery,et al.  Risk of selected serious cardiac events among new users of antihistamines. , 1995, Clinical therapeutics.

[2]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[3]  C. Spencer,et al.  Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. , 2000, Drugs & aging.

[4]  R. Stern,et al.  Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. , 1988, The Journal of investigative dermatology.

[5]  Elisabetta Poluzzi,et al.  Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus , 2001, European Journal of Clinical Pharmacology.

[6]  R. Paffenbarger,et al.  Comparison of National Death Index and World Wide Web death searches. , 2000, American journal of epidemiology.

[7]  A. B. Prasad,et al.  British National Formulary , 1994 .

[8]  F. Cambien,et al.  Do patients with low tension glaucoma have particular cardiovascular characteristics? , 1984, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[9]  S. Greenland,et al.  Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.

[10]  S. Ayis,et al.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.

[11]  Disciplinary Committee,et al.  Royal Pharmaceutical Society of Great Britain , 2002 .

[12]  C. Zarate,et al.  Sudden cardiac death and antipsychotic drugs: do we know enough? , 2001, Archives of general psychiatry.

[13]  I. Whyte,et al.  Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. , 1995, Journal of toxicology. Clinical toxicology.

[14]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[15]  J Benichou,et al.  A comparison of several methods to test for the existence of a monotonic dose–response relationship in clinical and epidemiological studies , 2001, Statistics in medicine.

[16]  W A Ray,et al.  Antipsychotics and the risk of sudden cardiac death. , 2001, Archives of general psychiatry.

[17]  D. Margolis,et al.  The risk of malignancy associated with psoriasis. , 2001, Archives of dermatology.